US FDA approves Ardelyx's kidney disease-related drug
Adds debt financing details from statement in paragraphs 6-7 and background paragraph 8 onwards
Oct 17 (Reuters) -The U.S. Food and Drug Administration (FDA) has approved Ardelyx's ARDX.O drug to treat high phosphate levels in patients with chronic kidney disease (CKD), the company said on Tuesday, more than two years after it was initially rejected.
The drug, branded as Xphozah, was approved to treat hyperphosphatemia, a condition resulting in an abnormally elevated level of phosphorus in the blood.
Excess phosphorus can remove calcium from bones and other parts of the body, which in turn can cause brittle bones, joint pain, muscle cramps and itchy skin.
The FDA has approved the drug for use in patients who have had an inadequate response or intolerance to phosphate binder therapies, the current standard-of-care treatment for the condition.
The company said a commercial launch for the drug is underway, adding that it expects to make the drug available in November.
In a separate statement, Ardelyx said it has amended its 2022 debt financing agreement with investment affiliates managed by SLR Capital Partners (SLR) to access an additional $50 million, which could be further increased by $50 million.
Ardelyx said it expects to draw the second tranche of this debt financing in October to support the commercial launch of Xphozah.
The U.S. health regulator had declined approval for Xphozah, chemically known as tenapanor, in 2021, citing unclear treatment benefits. It reconsidered and called an advisory panel meeting following the company's appeal.
The FDA's outside advisers, however, recommended Xphozah's approval last year as a single therapy or alongside existing treatment for treating high blood phosphate levels in dialysis patients.
Xphozah belongs to a class of drugs called phosphate absorption inhibitor that targets a protein in the gut responsible for the absorption of phosphorus.
Reporting by Kanjyik Ghosh, Mariam Sunny, Khushi Mandowara and Leroy Leo in Bengaluru; Editing by Shinjini Ganguli, Devika Syamnath and Subhranshu Sahu
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
